I-131 capsule and solution for diagnosis and therapy

I-131 hard capsules for diagnosis and therapy

  • Product name
    Product code
    ATC code
    Marketing Auth. No.
    Pharmaceutical Form and Description
    Activity per capsule
    Radionuclidic purity
    Radiochemical purity
    Expiry time
    Indications and Phosology
    Storage
    Packaging
    SPC
    SPC/RU
  • ThyroTop D 0.5-37 MBq hard capsule complies with the European Pharmacopoeia 0938 monograph
    I-RA-7/D
    V09F
    OGYI-T-9681/05
    Hard capsule, size “0”, colourless, transparent, CONI-SNAP type gelatine capsule, containing I-131 labelled sodium iodide, for oral administration.
    0.5-37 MBq
    131I ≥ 99.9 %
    ≥ 95 %
    21 days from the manufacturing date
    Thyroid diagnostics
    • 0.2-0.5 MBq capsule for radioiodine uptake of thyroid in case no accurate dosimetry is needed.
    • 2-4 MBq capsule can be used for calculation of personalised dose for the radionuclide therapy and thyroid scintigraphy for the establishment of the size of the hyperfunctioning tissue in thyroid nodules.
    • For whole body radioiodine scintigraphy in differentiated thyroid cancer 37-185 MBq (usually 74-111 MBq) I-131 is needed. 2-3 capsules should be administered per os.
    Do not store above 25 ºC. Store in the original packaging. Comply with the regulations for radiation safety.
    1-10 capsules in type I injection vial, closed with brombutyl stopper and green aluminium cap in lead container with paper insert.
  • I-131-sodium-iodide ThyroTop 38-7400 MBq hard capsules complies with the European Pharmacopoeia 2116 monograph
    I-RA-7/K
    V10XA01
    OGYI-T-9681/01
    Hard capsule, size “0”, colourless, transparent, CONI-SNAP type gelatine capsule, containing I-131 labelled sodium iodide, for oral administration.
    38-7400 MBq
    131I ≥ 99.9 %
    ≥ 95 %
    21 days from the manufacturing date
    Radionuclide therapy Treatment of hyperthyreosis
    • Graves disease.
    • Hyperfunctioning adenoma.
    • Non immunogenic diffuse goiter.
    Treatment of thyroid carcinoma
    • Ablation of residual thyroid tissues following thyroid cancer surgery and treatment of recidivations and metastases.
    • Required amount of activity is administered per os in one or max. 2 capsules
    Do not store above 25 ºC. Store in the original packaging. Comply with the regulations for radiation safety.
    1 capsule in a plastic insert with screwed cap placed into a lead container with wall thickness of 15-38 mm.

I-131 MIBG 20 MBq/ml injection for diagnostic use

  • Product code
    Pharmaceutical form and description
    Activity per vial
    Specific activity
    Radioactive concentration
    Radionuclid impurities
    Radiochemical purity
    pH
    Expiry date
    Indications and posology
    Recommended dose
    Storage
    Packaging
    SPC
    SPC/RU
  • I-RAO-1
    Radioactive sterile injection solution. The active ingredient of the radioactive solution for injection for intravenous use is I-131 radioisotope labelled meta-iodobenzyl-guanidine (MIBG).
    20 MBq, 40 MBq, or 80 MBq at activity reference date and time
    ≥ 26.7 GBq/g MIBG at activity reference date and time
    20 MBq/ml at activity reference date and time
    ≤ 0.1%
    ≥ 95%
    5–7
    5 days from manufacturing date
    Indication field: radioisotope diagnostics Localisation and imaging of neuroendocrine tumours, especially:phaeochromocytomaneuroblastoma
    The recommended individual patient dose is 20–40 MBq I-131-MIBG
    To prevent the uptake of the free radioiodine evolving in vivo, thyroid blockade is recommended before the examination. The injection should be administered slowly; time of administration is 2-4 minutes. Rapid administration of MIBG can result in blood pressure increase, allergic symptoms, flush or asthmatic spasms.
    Store in refrigerator at 2–8°C. Comply with the regulations for radiation safety.
    In type I injection vial (6R) closed with brombutyl stopper and green aluminium cap in lead container with paper insert. Transported in a Type A package

I-131 MIBG 370 MBq/ml injection for therapy

  • Product code
    Pharmaceutical form and description
    Activity per vial
    Specific activity
    Radioactive concentration
    Radionuclid impurities
    Radiochemical purity
    pH
    Expiry date
    Indications and posology
    Recommended dose
    Storage
    Packaging
    SPC
    SPC/RU
  • I-RAO-2
    Radioactive sterile solution for injection. For intravenous use. The active ingredient of the radioactive solution for injection for intravenous use is I-131 radioisotope labelled meta-iodobenzylguanidine (MIBG)
    3300-4100 MBq at activity reference date and time
    ≥ 555 GBq/g at activity reference date and time
    333-410 MBq/ml at activity reference date and time
    ≤ 0.1%
    ≥ 90%
    5-5.5
    5 days from manufacturing date
    RADIOISOTOPE THERAPY Local, lesion-specific treatment of neuro-endocrine tumours, especially:
    • phaeochromocytoma
    • neuroblastoma
    • paraganglioma
    • medullar thyroid carcinoma
    • carcinoid
    The recommended individual dose is 3.3–4.1 GBq.
    To prevent the uptake of the free radioiodine evolving in vivo, thyroid blockade is recommended before the examination. Do not administer the injection directly. 10 ml of the MIBG solution for injection must be mixed with 90 ml of 5% glucose injection. The obtained solution which has a total volume of 100 ml should be administered to the patient slowly. Time of administration is 2 – 4 hours. Rapid administration of MIBG can result in blood pressure increase, allergic symptoms, flush or asthmatic spasms.
    Store in a freezer, below -18°C. Storage of radiopharmaceuticals should be in accordance with national regulation on radioactive material. To ensure the low temperature during shipping dry-ice is used to cool the container.
    In type I injection vial (10R), closed with brombutyl stopper and green aluminium cap in lead container with paper insert. Transported in a Type A package

Cookies help us deliver our services. By using our services, you agree to our use of cookies. More Information

Important notice

The information on these pages is intended for use only by knowledgeable and experienced professionals working in the healthcare and medical industry.

By continuing, you automatically confirm that you are a professional working for a healthcare provider in your territory.